top of page

Recludix will have initial clinical data for its SH2 STAT6 soon (2H 2026) - while it already made waves via a big partnership, a positive profile in humans could signal that SH2's time has arrived

  • 2 hours ago
  • 1 min read

CEO Nancy Whiting walks us through the biology of SH2 and the potential breadth of it as a therapeutics approach (there are 120 SH2 domains). The lead STAT6 program is in healthy volunters, and the company is also working on a BTK. Plus, her thoughts on HHS's new initiative to speed up clinical trials in the United States.




Chapters

Her thoughts on HHS's new trials initiative - 2:39

Recludix's work on SH2 - 6:51



Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page